Healthcare | April 23, 2025
Paras Healthcare introduces radiation oncology facility at Ranchi
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
Subscribe To Our Newsletter & Stay Updated
